Gen1E Lifesciences
Gen1E Lifesciences is a clinical-stage biotech that uses its proprietary GRID AI/ML platform to develop first-in-class dual signal modulators for inflammatory and rare diseases, with lead compound GEn-1124 in Phase 2 for ARDS.
- Company typePrivate
- Founded2018
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gen1E Lifesciences does
Gen1E Lifesciences is a clinical-stage biotechnology company founded in 2018 and headquartered in Palo Alto, California, with additional research facilities in Mountain View, California and an office in Baltimore, Maryland. The company develops first-in-class precision therapies for inflammatory and rare diseases, organized around a proprietary AI/ML platform branded GRID that spans the entire drug development chain from target identification through clinical trials. The platform applies neural networks, gradient boosting methods, and hidden Markov models to curated public and proprietary multi-omics data to perform disease-drug mapping, identify allosteric binding pockets, and enable patient endotyping for precision medicine. Its scientific differentiator is a class of Dual Signal Modulators targeting the p38α:MK2 pathway that inhibit inflammatory signaling while sparing the anti-inflammatory MSK1/2 pathway, addressing the historical failure mode of prior-generation kinase inhibitors that were immunosuppressive and broadly toxic.
The company's pipeline comprises four assets across two kinase targets and three therapeutic areas: lead GEn-1124 IV in Phase 2 for Acute Respiratory Distress Syndrome (ARDS, developed in partnership with BARDA), oral formulations GEn-1124 and GEn-1123 in preclinical stages for chronic and rare chronic inflammatory indications, and NextGen ERK 1/2 Modulators in preclinical development for immuno-oncology. Gen1E has produced more than 21 first-in-class compounds and secured three FDA designations: Orphan Drug and Rare Pediatric Disease Designations for Duchenne Muscular Dystrophy, and Fast Track Designation for GEn-1124 in ARDS. Strategic and technology partners include BARDA, Vituity/Inflect Health, NVIDIA, Rubicon Research, and Olink Proteomics, with investors including Khosla Ventures, Clear Ventures, Y Combinator, Stanford StartX, Endurance28, Gaingels, and UM Ventures. The company is venture-backed and privately held, with no disclosed product revenue; future economics are expected to flow from drug commercialization, licensing royalties, and partnership milestones following regulatory approval.
Gen1E Lifesciences firmographics
Firmographics- Name
- Gen1E Lifesciences
- Legal name
- GEn1E Lifesciences Inc.
- Website
- https://gen1e.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gen1E Lifesciences is a clinical-stage biotech that uses its proprietary GRID AI/ML platform to develop first-in-class dual signal modulators for inflammatory and rare diseases, with lead compound GEn-1124 in Phase 2 for ARDS.
- Ownership category
- akta.pro rank
Gen1E Lifesciences industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Gen1E Lifesciences is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Gen1E Lifesciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biotech developing novel therapeutics. Revenue generation will come from drug commercialization upon FDA approval, potential licensing deals, and partnership milestones.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels8 records
Gen1E Lifesciences product offering
Product offeringCore offering
Gen1E Lifesciences is a clinical-stage biotech that uses its proprietary GRID AI/ML platform to discover and develop first-in-class Dual Signal Modulators (p38α:MK2) for inflammatory and rare diseases. Its lead asset, GEn-1124 IV, is in Phase 2 clinical trials for Acute Respiratory Distress Syndrome (ARDS), with additional oral candidates and NextGen ERK 1/2 modulators in development for chronic inflammatory and immuno-oncology indications.
Product overview
Gen1E Lifesciences is a clinical-stage, Phase 2 biotech company developing first-in-class precision therapies for inflammatory and rare diseases. The company operates with a 'Platform-in-a-Mechanism' model, combining its proprietary GRID AI Platform with a pipeline of novel dual signal modulators targeting p38α:MK2 and ERK pathways. Lead compound GEn-1124 IV is in Phase 2 for ARDS, with additional oral formulations (GEn-1124 Oral, GEn-1123 Oral) in development for chronic and rare chronic inflammatory conditions, plus NextGen ERK 1/2 Modulators for immuno-oncology. The company accelerated from early discovery to Phase 2 in 2.5 years with seed capital, leveraging its AI platform for disease endotyping, drug-disease mapping, and biomarker analysis.
Differentiator
Problem solved
Functional benefit
Brands
- GRID AI Platform: AI/ML platform for drug discovery that spans the entire process from Discovery to Clinical Studies, using Neural Networks, Gradient Boosting Methods and Hidden Markov Models.
Products and services
- GRID AI Platform
- GEn-1124 IV
- GEn-1124 Oral
- GEn-1123 Oral
- NextGen ERK 1/2 Modulators
Quantifiable outcome
- 40%+ mortality rate in ARDS patients with no FDA-approved treatment currently available
- +3 more outcomes
Companies that use Gen1E Lifesciences
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles3 records
Gen1E Lifesciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Gen1E Lifesciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major and supporting.
- Rubicon Research LimitedcoreIndia-based pharmaceutical formulations company entered into definitive agreement with Gen1E Lifesciences for strategic partnership to advance AI-driven precision immunomodulators.
- BARDA (Biomedical Advanced Research and Development Authority)corePartnership with BARDA to advance AI-powered endotyping program for ARDS patients and accelerate GEn-1124 development. BARDA is a U.S. government agency focused on pandemic preparedness and medical countermeasures for infectious disease threats.
- VituitycoreNetwork of 6,000+ physicians in 700 hospitals; partnership with BARDA and Vituity mentioned in differentiation milestones. Inflect Health is Vituity's innovation arm.
- Inflect HealthmajorStrategic partnership expanded with GEn1E to combat rare and inflammatory diseases; Vituity's healthcare innovation subsidiary.
- NVIDIAsupportingStrategic partner providing AI/compute infrastructure for GRID platform development.
- Olink ProteomicssupportingPartnership utilizing Olink's multiplex proteomics technology for measuring thousands of proteins in small samples; enabled proteomics analysis in Phase 1 study.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Gen1E Lifesciences competitors and assessment
Company assessmentDirect peers
- Schrödinger: Computational drug discovery platform combining physics-based simulation with machine learning to accelerate small molecule therapeutics. Direct competitor in computational chemistry and AI-driven drug design, with both proprietary pipeline and software business model.
- Exscientia: AI-driven pharmaceutical company using end-to-end platform to design and develop novel small molecule therapeutics. Direct competitor in AI-driven precision medicine with similar patient endotyping and drug-disease matching approach.
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics for metabolic and neurological diseases. Comparable platform approach using ML models trained on multi-omics data for target identification and drug discovery.
- BioXcel Therapeutics: Clinical-stage biopharmaceutical company using AI platform to identify and develop transformative medicines in neuroscience and immuno-oncology. Direct peer in AI-driven drug discovery applied to inflammatory and rare disease indications.
- Recursion Pharmaceuticals: Clinical-stage AI/ML drug discovery company using high-throughput biology and machine learning to identify novel therapeutics across multiple therapeutic areas. Direct competitor in AI-driven small molecule discovery with comparable platform-in-a-pipeline model.
Emerging players
- Atomwise: AI-driven small molecule drug discovery company using structure-based design and ML to identify novel compounds across multiple therapeutic areas. Comparable AI platform approach but broader pharma partnerships and earlier stage programs than Gen1E.
- Athersys: Clinical-stage biotechnology company developing cell therapy and immunology products for critical care indications including ARDS. Direct competitor in ARDS therapeutic space with overlapping patient population and clinical endpoints.
- Aclaris Therapeutics: Clinical-stage biopharmaceutical company developing novel kinase inhibitors for inflammatory and immunological diseases. Comparable therapeutic focus on kinase dysregulation in inflammatory diseases, though uses traditional ATP-competitive inhibitors.
Broad incumbents
- Galapagos NV: Mid-cap European biopharmaceutical company developing small molecule kinase inhibitors for inflammatory diseases and fibrosis. Broad incumbent in kinase inhibitor space with deeper pipeline and resources, though focused on different specific targets than Gen1E's p38α:MK2.
- Moderna: Clinical-stage to commercial mRNA therapeutics company with similar Phase 2-stage origin in rare and inflammatory disease research. Shares board director (François Nader) with Gen1E and represents the type of platform-scale biotech Gen1E could become.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Customer concentration
Gen1E Lifesciences social profiles
Digital presenceGen1E Lifesciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gen1E Lifesciences leadership team
Management profileNumber of profiles
Profiles8 records
Gen1E Lifesciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gen1E Lifesciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gen1E Lifesciences
What does Gen1E Lifesciences do?
Gen1E Lifesciences is a clinical-stage biotech that uses its proprietary GRID AI/ML platform to discover and develop first-in-class Dual Signal Modulators (p38α:MK2) for inflammatory and rare diseases. Its lead asset, GEn-1124 IV, is in Phase 2 clinical trials for Acute Respiratory Distress Syndrome (ARDS), with additional oral candidates and NextGen ERK 1/2 modulators in development for chronic inflammatory and immuno-oncology indications.
Is Gen1E Lifesciences a public or private company?
Gen1E Lifesciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gen1E Lifesciences founded?
Gen1E Lifesciences was founded in 2018. It employs 11 to 50 people.
Where is Gen1E Lifesciences based?
Gen1E Lifesciences is headquartered in Palo Alto, United States, in the North America region.
How does Gen1E Lifesciences make money?
One revenue line is on record: drug Development and Commercialization.
Who are Gen1E Lifesciences's main competitors?
Direct peers on record are Schrödinger, Exscientia, Insitro, BioXcel Therapeutics and Recursion Pharmaceuticals. Emerging players are Atomwise, Athersys and Aclaris Therapeutics. Broad incumbents are Galapagos NV and Moderna.
Does Gen1E Lifesciences have an API?
No public API is recorded for Gen1E Lifesciences.
What industry is Gen1E Lifesciences in?
Gen1E Lifesciences's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 2834.